Navigation Links
Silence Therapeutics Announces Subscription and Open Offer to Raise up to £5.7 Million
Date:7/11/2012

655 in patients with diabetic macular oedema. The trial is designed to compare the efficacy of PF-'655 when used alone or in combination with Lucentis (Novartis/Roche) against Lucentis in patients with diabetic macular oedema. The trial is expected to complete in the middle of 2014. In May 2012, Quark also announced it had amended its agreement with Pfizer to enable it to initiate a 108 patient Phase IIa trial of PF-'655 in patients with open-angle glaucoma (the most common type of glaucoma). Quark and Pfizer have also conducted a Phase II trial of PF-'655 in age-related macular degeneration, the leading cause of blindness in the elderly. In addition to royalties on product sales, milestones from these programmes could now total up to $120 million of which $6 million has been received to date. A further milestone of almost $4 million is due to Silence on initiation of a Phase III trial.

In addition to PF-'655, Quark is also developing QPI-1002 for the prevention of delayed graft function in kidney transplant patients and for the prevention of acute kidney injury. QPI-1002 is based on Silence AtuRNAi technology. In August 2010, Quark signed an option and licence agreement for QPI-1002 with Novartis for an upfront payment of $10 million. Quark is currently conducting a 366 patient Phase II trial of QPI-1002 in prevention of delayed graft function in kidney transplant patients. The trial is due to be completed before the end of 2012. Based on the results of this study, Novartis may decide to exercise its option to license QPI-1002. Quark also plans to initiate a Phase II trial of QPI-1002 in acute kidney injury.  In addition to royalties on product sales, milestones to Silence from these programmes could total up to $100 million.

During the last 12 months, Silence has signed a number of delivery collaborations to evaluate the Company's three RNAi delivery systems including agreements with InteRNA Technologies BV, miRagen Inc. and Mirna Inc. Discussio
'/>"/>

SOURCE Silence Therapeutics Plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
2. Silence Therapeutics Announces Board Changes and Appointment of New Chief Executive Officer
3. Silence Therapeutics Additional Listing
4. Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
5. Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office
6. Nektar Therapeutics Announces Private Placement of $125 Million of Senior Secured Notes Due in 2017
7. Bio-Innovator Saneron CCEL Therapeutics Supports Cryo-Cell International Leadership and Board of Directors in Proxy Contest
8. Global Neuroendocrine Carcinoma Therapeutics Market To Reach $475m By 2019 - Report
9. United Therapeutics Announces Additional $100 Million Share Repurchase Program
10. Healthpoint Biotherapeutics To Create State-of-the-Art Cell Sciences Manufacturing Facility
11. ResearchMoz: Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar- Market Research Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014 Scientists at NYU Langone Medical Center have ... of the process for turning adult cells into so-called ... vitamin C. Using the new technique in mice, the ... adult skin cells by more than 20-fold compared with ... and reliable, and thus should generally accelerate research aimed ...
(Date:9/19/2014)... , Sept. 19, 2014  Nektar Therapeutics ... from preclinical studies characterizing the analgesic profiles of ... kappa opioid receptor agonist molecules. The preclinical research ... medicinal chemistry platform. The analgesic properties ... the medical literature. 1,2 Kappa opioid receptors ...
(Date:9/19/2014)... Dublin ... announced the addition of the  "Micro Market Monitor ... offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ... fastest-growing segments in the chromatography market. The market ... expected to reach $2.0 billion by 2019, at ...
(Date:9/18/2014)... , Sept. 18, 2014 About ... testing, is performed outside a clinical laboratory. It ... in administrating appropriate treatments and medication. POCT is ... prevalence of lifestyle diseases such as diabetes, heart ... user-friendly. POCT devices are standardized to minimize errors ...
Breaking Biology Technology:NYU Langone scientists report reliable and highly efficient method for making stem cells 2NYU Langone scientists report reliable and highly efficient method for making stem cells 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5Micro Market Monitor : Global Pre-packed Chromatography Columns 2POCT Market in China 2014-2018 2
... New BioPharma Intelligence Resource Set to Give Industry Leaders the Edge -- OXFORD, England, October 21, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed ...
... ACCESS PHARMACEUTICALS, INC. (OTC ... leveraging its proprietary drug-delivery platforms to develop treatments in ... it has submitted additional patent applications, covering its Cobalamin-mediated ... injectable drugs, as a result of the growing interest ...
... HONG KONG, Oct. 20 /PRNewswire-Asia-FirstCall/ -- ... ... lpUnit=,PRN,; --> ... ,; var first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var ...
Cached Biology Technology:A New BioPharma Intelligence Resource Set to Give Industry Leaders the Edge 2A New BioPharma Intelligence Resource Set to Give Industry Leaders the Edge 3A New BioPharma Intelligence Resource Set to Give Industry Leaders the Edge 4A New BioPharma Intelligence Resource Set to Give Industry Leaders the Edge 5A New BioPharma Intelligence Resource Set to Give Industry Leaders the Edge 6A New BioPharma Intelligence Resource Set to Give Industry Leaders the Edge 7A New BioPharma Intelligence Resource Set to Give Industry Leaders the Edge 8A New BioPharma Intelligence Resource Set to Give Industry Leaders the Edge 9Access Pharmaceuticals Files Additional IP For Cobalamin Oral Delivery Technology 2Access Pharmaceuticals Files Additional IP For Cobalamin Oral Delivery Technology 3China Cord Blood Corporation Files Its Annual Report on Form 20-F/A 2China Cord Blood Corporation Files Its Annual Report on Form 20-F/A 3China Cord Blood Corporation Files Its Annual Report on Form 20-F/A 4China Cord Blood Corporation Files Its Annual Report on Form 20-F/A 5China Cord Blood Corporation Files Its Annual Report on Form 20-F/A 6China Cord Blood Corporation Files Its Annual Report on Form 20-F/A 7China Cord Blood Corporation Files Its Annual Report on Form 20-F/A 8
(Date:9/19/2014)... professor will study multifunctional and specialized spinal cord ... National Science Foundation grant in the amount of ... professor in the Department of Biology, OU College ... differences between the multifunctional and specialized spinal cord ... and what connections they make. Berkowitz will ...
(Date:9/18/2014)... - Washington State University researchers have developed a unique ... power waste cleanup in rural areas. , The ... an inexpensive and quick way to clean up waste ... while reducing pollution. , Professor Haluk Beyenal and ... Engineering and Architecture discuss the system in the online ...
(Date:9/18/2014)... A novel robotic system that can operate inside the ... as part of a biomedical research partnership program at ... of determining if the robot, in conjunction with real-time ... accurate, less costly, and less discomforting for the patient. ... prostate cancer therapies with greater precision. , Developed by ...
Breaking Biology News(10 mins):Researchers develop unique waste cleanup for rural areas 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5
... resources at the U.S. Department of Energy,s (DOE) ... how proteins misfold to create the tissue-damaging structures ... called amyloid fibrils, are also implicated in neurodegenerative ... prion diseases like Creutzfeldt-Jacob and mad cow disease., ...
... to KATC Channel 3 in Lafayette, LA on December 17, ... around Acadiana (the mostly French region of Louisiana in the ... instead controlled-sugar cane burns. But some residents living near the ... comfort. From a distance, these fires look like an ...
... trichopoda , a sprawling shrub that grows on just a ... plant in its family and genus. It is also one ... about 200 million years ago. Now, researchers from Indiana University, ... JGI), Penn State University, and the Institute of Research for ...
Cached Biology News:A wrong molecular turn leads down the path to Type 2 diabetes 2A wrong molecular turn leads down the path to Type 2 diabetes 3A gluttonous plant reveals how its cellular power plant devours foreign DNA 2A gluttonous plant reveals how its cellular power plant devours foreign DNA 3
... Immulon 2HB ELISA ... provide increased binding affinity for hydrophilic ... bottom works well for reagent injection ... Each strip accomodates ...
... The MX80 Series of positioning slides ... motor, ballscrew, leadscrew, micrometer, and manual. ... high performance, cost-effective multi-axis systems. These ... bearings, encoder resolutions down to 10 ...
Ethylene glycol-bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid, Molecular Biology Grade...
Ethylene glycol-bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid, Molecular Biology Grade...
Biology Products: